

1 Vanessa R. Waldref  
2 United States Attorney  
3 Eastern District of Washington  
4 Brian M. Donovan  
5 John T. Drake  
6 Assistant United States Attorneys  
7 Post Office Box 1494  
8 Spokane, WA 99210-1494  
9 Telephone: (509) 353-2767  
10

11 UNITED STATES DISTRICT COURT  
12 FOR THE EASTERN DISTRICT OF WASHINGTON  
13

14 JEREMY OLSEN,

15 Plaintiff,

16 v.

17 XAVIER BECERRA, in his official  
18 capacity as Secretary of the United States  
19 Department of Health and Human  
20 Services,

21 Defendant.

No. 2:21-CV-00326-TOR

DEFENDANT'S CROSS-MOTION  
FOR SUMMARY JUDGMENT

11/22/22 at 2:30 p.m.  
With Oral Argument

22 I. INTRODUCTION

23 This is a case that never should have been filed. The Medicare claims at issue  
24 were paid *four months* before Plaintiff filed his complaint. The claims were paid in  
25 accordance with a judgment Plaintiff obtained in a prior case, *Olsen I*. The payment  
26 of these claims means that Plaintiff received the Medicare coverage to which he was  
27 entitled—and that, as a result, there is no Article III case or controversy for this Court  
28 to resolve. The case should be dismissed for lack of jurisdiction.

1 Separately, the administrative ruling Plaintiff is challenging, CMS 1682-R (Jan.  
2 12, 2017), has been formally rescinded and replaced by the Secretary through notice-  
3 and-comment rulemaking and a recent administrative ruling, CMS 1738-R (May 13,  
4 2022). The Secretary's new policy provides coverage for virtually all continuous  
5 glucose monitor ("CGM") devices, including "non-therapeutic" devices for which  
6 coverage was formerly excluded under CMS 1682-R. As the Tenth Circuit recently  
7 recognized in a companion case with nearly identical claims, this new policy renders  
8 any challenge to CMS 1682-R moot. *Smith v. Becerra*, 44 F.4th 1238 (10th Cir.  
9 2022). The fact that Plaintiff's challenge to CMS 1682-R is moot independently  
10 warrants dismissal for lack of jurisdiction.  
11  
12  
13

## 14 II. FACTS

15 There are two Medicare reimbursement claims at issue in this case: (1) a claim  
16 for CGM sensors with a date of service of April 19 – July 18, 2019 (the "April 2019  
17 claim"), and (2) a claim for CGM sensors with a date of service of March 10, 2021  
18 (the "March 2021 claim"). As outlined below, both claims were paid by Medicare on  
19 July 15, 2021. The claims were paid in recognition of a judgment Plaintiff obtained  
20 against the Secretary in a prior case, *Olsen v. Becerra*, Case No. 20-CV-00374-SMJ  
21 (E.D. Wash.) ("*Olsen I*"), which held that Plaintiff's CGM device met the definition  
22 of "durable medical equipment" for which Medicare is required to provide coverage.  
23  
24  
25

26 Three months *after* the Secretary paid the claims, an Administrative Law Judge  
27 ("ALJ") and the Medicare Appeals Council issued decisions that purport to deny  
28

1 coverage. The ALJ and the Medicare Appeals Council were not aware of the *Olsen I*  
2 judgment, or the fact that the claims had already been paid, when they issued their  
3 decisions. To the extent these decisions amount to “denials” of the claims, they exist  
4 on paper only, and have not impacted Plaintiff in any way.  
5

6 A. *Olsen I* Proceedings (2019-2021)

7 Plaintiff filed the *Olsen I* case in 2019. His claims in that case challenged  
8 Medicare’s denial of coverage for the specific type of CGM device Plaintiff uses.  
9 This Court (Judge Mendoza) entered summary judgment for Plaintiff, holding that  
10 Plaintiff’s CGM device meets the definition of “durable medical equipment” under the  
11 Medicare regulations, and must therefore be covered. *Olsen I*, ECF No. 39. The  
12 summary judgment order was entered on February 23, 2021. *Id.* Thereafter, on April  
13 20, 2021, the Court awarded Plaintiff attorney’s fees and costs under the Equal Access  
14 to Justice Act. *Id.* at ECF No. 50. The order awarding fees and costs contained a  
15 finding that the government’s litigation position was “so obviously wrong as to be  
16 frivolous.” *Id.*  
17  
18  
19  
20

21 B. Payment of April 2019 and March 2021 Claims (July 2021)

22 The April 2019 and March 2021 claims were paid by Medicare on **July 15,**  
23 **2021.** AR 566.<sup>1</sup> Payment was issued by the Secretary’s Medicare Administrative  
24 Contractor, Noridian Healthcare Solutions (“Noridian”), to the company that supplied  
25  
26  
27

---

28 <sup>1</sup> “AR” refers to the Administrative Record filed at ECF No. 32.

1 Plaintiff with the CGM sensors, MiniMed Distribution Corp. (“MiniMed”). AR 532,  
2 539-40. The Secretary paid these claims in accordance with the *Olsen I* judgment,  
3 which the Secretary viewed as having an issue preclusive effect on all of Plaintiff’s  
4 then-pending and future CGM claims. AR 510-31; ECF No. 42-1 at ¶¶ 6-7, 9. The  
5 April 2019 and March 2021 claims were paid at the same time as nine other CGM  
6 claims Plaintiff had submitted to Medicare before the *Olsen I* judgment. AR 539-40,  
7 566-69; ECF No. 41 at ¶ 76.  
8  
9

10 C. Post-Payment Administrative Claim “Denials” (October 2021)

11 Three months *after* the Secretary paid the claims, the ALJ and the Medicare  
12 Appeals Council issued administrative decisions that purport to deny coverage for the  
13 claims. Those decisions were issued on October 22, 2021 (as to the April 2019 claim)  
14 (AR 3-12), and October 26, 2021 (as to the March 2021 claim) (AR 385-90). Both  
15 decisions purport to deny coverage under an administrative ruling (which has since  
16 been replaced and rescinded) known as CMS 1682-R.  
17  
18

19 //

20 //

21 //

22 //

23 //

24 //

25 //

26 //

27 //

28 //

The timing of these decisions is crucial. Below is a chronological summary:

<b>April 2019 Claim</b>	<b>Date</b>
Initial Denial by Noridian (MAC)	6/14/2019
Redetermination Request (MAC)	7/5/2019
Redetermination Decision (MAC)	7/25/2019
Reconsideration Request (QIC)	10/7/2019
Reconsideration Decision (QIC)	11/26/2019
ALJ Hearing Request	12/3/2019
ALJ Hearing	1/8/2020
ALJ Decision	1/31/2020
Appeal to Medicare Appeals Council	2/11/2020
<i>Olsen I</i> Judgment	2/23/2021
<i>Olsen I</i> Attorney's Fees Ruling	4/20/2021
<b>CLAIM PAID</b>	7/15/2021
<b>Medicare Appeals Council Decision (Challenged Decision)</b>	<b>10/22/2021</b>

<b>March 2021 Claim</b>	<b>Date</b>
<i>Olsen I</i> Judgment	2/23/2021
Initial Denial by Noridian (MAC)	4/16/2021
<i>Olsen I</i> Attorney's Fees Ruling	4/20/2021
Redetermination Request (MAC)	5/3/2021
Redetermination Decision (MAC)	6/16/2021
Reconsideration Request (QIC)	6/30/2021
<b>CLAIM PAID</b>	7/15/2021
Reconsideration Decision (QIC)	8/24/2021
ALJ Hearing Request	9/7/2021
ALJ Hearing	10/8/2021
<b>ALJ Decision (Challenged Decision)</b>	<b>10/26/2021</b>

1 The fact that the ALJ and the Medicare Appeals Council “denied” the claims  
2 three months after the Secretary paid them in accordance with the *Olsen I* judgment is  
3 admittedly odd. But the explanation is simple: neither tribunal was aware of the *Olsen*  
4 *I* judgment, or the fact that the claims had already been paid in accordance with that  
5 judgment. ECF No. 42-1 at ¶ 11.  
6

7 Both parties are partly to blame for this unusual circumstance. The Secretary  
8 took the necessary steps to ensure that its claims processing contractor, Noridian, paid  
9 the claims in accordance with the *Olsen I* judgment. AR 510-31. The Secretary did  
10 not, however, communicate with the various entities that handle administrative  
11 appeals. ECF No. 42-1 at ¶ 11. The end result was that Noridian paid the claims, but  
12 the ALJ and the Medicare Appeals Council were not informed.  
13  
14

15 Plaintiff, for his part, did not advise the ALJ or the Medicare Appeals Council  
16 of the *Olsen I* judgment, or the fact that the Secretary had paid the claims. Plaintiff  
17 had a tailor-made opportunity to do so during a hearing before the ALJ on October 8,  
18 2021, but he remained silent. AR 391-98. Rather than transparently requesting that  
19 coverage be granted pursuant to the *Olsen I* judgment (or disclosing that the claims  
20 had already been paid), Plaintiff took the opposite approach, *insisting that the ALJ*  
21 *deny coverage* under CMS 1682-R. AR 395-98.  
22  
23  
24

25 In any case, the ALJ and Medicare Appeals Council decisions have no practical  
26 or legal effect. To the extent they can be construed as “denials” of the subject claims,  
27 the denials exist on paper only. They did not prevent Plaintiff from receiving the  
28

1 Medicare coverage to which he was entitled, or impact him in any other way, because  
2 the claims had been paid three months earlier.

3 D. The Secretary's Policy Changes Regarding CGM Coverage (2020-2022)  
4

5 Plaintiff challenges the administrative “denials” of the April 2019 and March  
6 2021 claims at least in part on the grounds that the denials were based on CMS 1682-  
7 R, which Plaintiff contends was issued illegally. CMS 1682-R distinguished between  
8 “therapeutic” (or “non-adjunctive”) CGM devices that were approved by the United  
9 States Food and Drug Administration (“FDA”) to be relied upon in making treatment  
10 decisions for managing diabetes, and “non-therapeutic” (or “adjunctive”) CGM  
11 devices, which had not received FDA approval. CMS 1682-R held that Medicare  
12 would cover the former category of CGMs, but not the latter.<sup>2</sup>  
13

14  
15 The Secretary, through the Centers for Medicare & Medicaid Services (“CMS”)  
16 has now rescinded and replaced CMS 1682-R, and extended Medicare coverage to all  
17 CGM devices, both therapeutic and non-therapeutic, with an exception not relevant  
18 here for devices that use a smartphone as the sole receiver. CMS accomplished this  
19 goal in stages. On November 4, 2020, CMS published a proposed rule, proposing to  
20 replace CMS 1682-R with a new rule that would generally classify CGM devices as  
21 durable medical equipment under Medicare Part B, regardless of whether the device  
22 was classified as therapeutic (“non-adjunctive”) or non-therapeutic (“adjunctive”). 85  
23  
24  
25  
26

27  
28 <sup>2</sup> At the time CMS 1682-R was issued in 2017, there was only one non-adjunctive  
CGM device that had been approved by the FDA: the Dexcom G5 CGM.

1 Fed. Reg. 70,358, 70,398–70,404 (Nov. 4, 2020). After receiving and considering  
2 public comment on the proposed rule, CMS issued its final rule on December 28,  
3 2021. 86 Fed. Reg. 73,860, 73,896–73,902 (Dec. 28, 2021) (the “DME Final Rule”),<sup>3</sup>  
4 available here. The DME Final Rule replaced CMS 1682-R and expanded the  
5 classification of durable medical equipment to both therapeutic and non-therapeutic  
6 CGMs. *Id.* at 73,902. Under the DME Final Rule, all CGM devices (except those that  
7 use a smartphone as the sole receiver)<sup>4</sup> are considered to be “primarily and  
8 customarily used to serve a medical purpose” and “durable medical equipment” as  
9 those terms are defined in the Medicare coverage regulations. *See id.* at 73,899. The  
10 DME Final Rule also clarified that CMS 1682-R “only addressed whether CGMs  
11 meet the Medicare definition of [durable medical equipment] and did not address  
12 whether insulin pumps that can also perform the function of a CGM are [durable  
13 medical equipment] since insulin pumps are already classified as [durable medical  
14 equipment].” *Id.* at 73,898. The agency recognized, however, that claims for  
15 continuous glucose-monitor sensors and transmitters used with insulin pumps “are  
16 being denied inappropriately based on CMS-1682-R.” *Id.* The DME Final Rule  
17 became effective February 28, 2022. *See id.* at 73,860.

18 CMS took additional steps to make this policy change apply to earlier dates of  
19  
20  
21  
22

23  
24  
25  
26 <sup>3</sup> The acronym DME refers to durable medical equipment. *See* 42 U.S.C. § 1395x(n).

27 <sup>4</sup> A smartphone does not fit the definition of durable medical equipment. *See* 42  
28 C.F.R. § 414.202. That limited exception does not apply to the claims at issue here.



1 service (*i.e.*, those prior to the February 28, 2022, effective date of the DME Final  
2 Rule). On February 25, 2022, CMS issued a technical direction letter, TDL-220257,  
3 to its Durable Medical Equipment Medicare Administrative Contractors (“DME  
4 MACs”), instructing them to apply the policy of the DME Final Rule to  
5 reimbursement claims with dates of service that predate the February 28, 2022  
6 effective date of the rule. *See* ECF No. 20-1 (TDL-220257 (Feb. 25, 2022)). TDL-  
7 220257 states:  
8  
9

10 The [DME Final Rule] replaced a 2017 CMS Ruling, CMS-1682-R  
11 (“2017 Ruling”), regarding CGMs. Pursuant to this [technical direction  
12 letter], the DME MACs shall apply the coverage and payment provisions  
13 of the [DME Final Rule] to valid reimbursement claims and appeals for  
14 CGM monitors or receivers and/or necessary supplies and accessories  
15 supplied prior to February 28, 2022. The [DME Final Rule] obviates the  
16 need for further application of the 2017 Ruling on CGMs, as CMS has  
17 determined that, in addition to therapeutic or nonadjunctive CGMs, non-  
18 therapeutic or adjunctive CGMs can also meet the Medicare definition of  
19 durable medical equipment (DME) at 42 C.F.R. § 414.402.

20 *Id.* at 1-2.

21 Finally, on May 13, 2022, the agency issued a new CMS Ruling that formally  
22 rescinds CMS 1682-R. That new ruling, CMS 1783-R, instructs contractors and  
23 Department of Health and Human Services employees at all levels of the Medicare  
24 claims-review process—including administrative law judges and the Medicare  
25 Appeals Council—to apply the terms of the DME Final Rule to valid pending or  
26 future claims and appeals, regardless of the date of service. ECF No. 44-1 (CMS  
27 1738-R (May 13, 2022)). CMS 1783-R explains that, “[t]aken together, the [DME  
28

1 Final Rule] and this Ruling prohibit further application of [CMS 1682-R] on CGMs,”  
2 *id.* at 6, and require application of CMS’s determination that “the following types of  
3 CGMs shall be classified as [durable medical equipment]: therapeutic or non-  
4 adjunctive CGMs; non-therapeutic or adjunctive CGMs; and insulin pumps that also  
5 function as a CGM or receiver,” *id.* at 11.  
6

7 Both TDL-220257 and CMS 1738-R apply to Medicare reimbursement claims  
8 that have been “valid[ly] appeal[ed].” TDL-220257 at 2-3; CMS 1738-R at 9-10.  
9

### 10 **III. ARGUMENT**

11 Subject matter jurisdiction is lacking for two independent reasons. First, the  
12 Secretary paid the April 2019 and March 2021 claims four months before the case was  
13 filed. For that reason, there is no “case or controversy” on which Article III  
14 jurisdiction can be predicated. Second, the Secretary has formally rescinded and  
15 replaced CMS 1682-R. That development moots Plaintiff’s challenges to CMS 1682-  
16 R and eliminates any jurisdiction that may have originally existed.  
17

18 Because jurisdiction is lacking, the Court lacks authority to take any action  
19 other than to dismiss the case without prejudice. However, if the Court concludes it  
20 does have jurisdiction, the appropriate course is to remand the case with instructions  
21 to vacate the administrative decisions that purport to deny coverage pursuant to the  
22 now-rescinded CMS 1682-R, which relief the Secretary has consented to from the  
23 very beginning.  
24  
25  
26  
27  
28

**A. The case should be dismissed for lack of Article III jurisdiction because the Medicare claims at issue were paid months before the case was filed.**

“Article III of the Constitution confines the judicial power of federal courts to deciding actual ‘Cases’ or ‘Controversies.’” *Hollingsworth v. Perry*, 570 U.S. 693, 704 (2013) (citing U.S. Const. Art. III § 2). “No principle is more fundamental to the judiciary’s proper role in our system of government[.]” *Raines v. Byrd*, 521 U.S. 811, 818 (1997). The presence of a disagreement, “however sharp and acrimonious it may be,” does not by itself satisfy the case or controversy requirement. *Hollingsworth*, 570 U.S. at 704 (quotation omitted). “The plaintiff must have (1) suffered an injury in fact, (2) that is fairly traceable to the challenged conduct of the defendant, and (3) that is likely to be redressed by a favorable judicial decision. *Spokeo, Inc. v. Robins*, 578 U.S. 330, 338 (2016). “The plaintiff, as the party invoking federal jurisdiction, bears the burden of establishing these elements.” *Id.*

It is undisputed that the Medicare claims at issue were paid more than four months before this case was filed. It is further undisputed that the administrative decisions from which Plaintiff appeals, which purport to deny coverage for the claims, did not have the effect of denying coverage. In short, it is undisputed that Plaintiff received the Medicare coverage to which he was entitled.

As a matter of law and simple common sense, these facts do not present a live case or controversy. There is no need for an order “direct[ing] the Secretary to *make appropriate payment for the claims*” as Plaintiff repeatedly prays for in his complaint.

1 ECF No. 1 at ¶¶ 92, 93, 95, 96, 98, 99, 101, 102, 104, 105 (emphasis added). The  
2 Secretary *has* made “appropriate payment” for the claims—and did so months before  
3 the case was filed. It is difficult to imagine a more textbook illustration of a case that  
4 does not meet this basic Article III jurisdictional requirement.  
5

6 Plaintiff may argue that a live controversy exists because the Secretary could  
7 seek “recoupment” of the payments in the future. That argument fails for two reasons.  
8 First, the argument is purely speculative. A mere possibility that the Secretary might  
9 seek recoupment at some unspecified time does not suffice. Plaintiff must show that  
10 recoupment of the payments is “actual or imminent, not conjectural or hypothetical.”  
11 *Lujan v. Defs. of Wildlife*, 504 U.S. 555, 560 (1992). Plaintiff cannot do so because  
12 the Secretary has no intention of clawing back the payments, which would contravene  
13 both the *Olsen I* judgment and the Secretary’s current policies.<sup>5</sup>  
14  
15  
16

17 Second, the only grounds on which the Secretary could theoretically pursue  
18 recoupment is that the claims were paid in contravention of the ALJ and Medicare  
19 Appeals Council decisions that purport to deny coverage. But those decisions rely on  
20 CMS 1682-R, which the Secretary has since formally rescinded and replaced through  
21  
22

---

23 <sup>5</sup> Any suggestion that the Secretary admitted in its answer that he might pursue  
24 recoupment (*see, e.g.*, ECF No. 22 at 6-7), is incorrect. No such admission was made.  
25 The complaint alleges that the Secretary can “recoup overpayments” pursuant to 42  
26 C.F.R. § 405.352 “if he determines that he has overpaid a claim.” ECF No. 1 at ¶ 78.  
27 That is an accurate statement of the law, which the Secretary admitted. The complaint  
28 does not allege that the Secretary has taken any steps toward pursuing recoupment of  
the payments at issue, or that he has plans to do so in the future. The Secretary has not  
taken any such steps, and has no plans to do so in the future.

1 notice and comment rulemaking and CMS 1738-R. Thus, even if the Secretary was  
2 inclined to pursue recoupment, which he is not, he would lack any legal justification  
3 for doing so. In short, recoupment is a red herring.  
4

5 In apparent recognition that his *own* claims do not present a live controversy,  
6 Plaintiff has recently resorted to asserting claims on behalf of other similarly-situated  
7 Medicare beneficiaries. *See, e.g.*, ECF No. 51 at 1-2 (arguing, without empirical  
8 support, that the Secretary is “responsible for the deaths of thousands of Americans”  
9 and that an injunction should issue to “bar[] the Secretary from repeating the conduct  
10 that killed so many”); ECF No. 64 at 11 (urging appointment of a special master to  
11 oversee all CGM claims submitted to Medicare by Type I diabetics). This tactic is  
12 unavailing. To establish Article III jurisdiction, Plaintiff must demonstrate an injury  
13 that is *personal to him*:  
14  
15

16  
17 The Art. III judicial power exists only to redress or otherwise to protect  
18 against injury *to the complaining party*, even though the court’s judgment  
19 may benefit others collaterally. A federal court’s jurisdiction therefore can  
20 be invoked *only when the plaintiff himself* has suffered some threatened or  
21 actual injury resulting from the putatively illegal action.

22 *Warth v. Seldin*, 422 U.S. 490, 498 (1975) (emphasis added) (quotation and citation  
23 omitted).

24 At bottom, this case should never have been filed. Plaintiff received the  
25 Medicare coverage to which he was entitled. Due to a miscommunication on the  
26 Secretary’s part, and what appears to have been calculated concealment on Plaintiff’s  
27 part, the ALJ and the Medicare Appeals Council issued after-the-fact decisions that  
28

1 purport to deny coverage. But those “denials” exist on paper only. They did not  
 2 impact Plaintiff in any way. The Court should reject Plaintiff’s bid to manufacture  
 3 Article III jurisdiction out of those meaningless pieces of paper.<sup>6</sup>  
 4

5 **B. Plaintiff’s challenges to CMS 1682-R and his requests for injunctive relief**  
 6 **and appointment of a special master are moot because CMS 1682-R has**  
 7 **been formally rescinded and replaced.**

8 For the reasons explained above, jurisdiction is lacking because the subject  
 9 claims were paid before the case was filed. But jurisdiction is also lacking for an  
 10 independent reason: the administrative ruling that Plaintiff is challenging, CMS 1682-  
 11 R, has been formally rescinded and replaced through notice and comment rulemaking  
 12 and CMS 1738-R. Those developments moot Plaintiff’s challenges to CMS 1682-R  
 13 and his request for permanent injunctive relief and appointment of a special master.  
 14

15 The Tenth Circuit’s recent decision in *Smith v. Becerra*, 44 F.4th 1238 (10th  
 16 Cir. 2022), is directly on point. The plaintiff in *Smith*, who was represented by the  
 17 same lead counsel who represents Plaintiff in this case, asserted claims to invalidate  
 18  
 19  
 20

---

21 <sup>6</sup> While not relevant for jurisdictional purposes, Defendant questions Plaintiff’s  
 22 motivation for filing the case. Plaintiff filed the case and immediately demanded that  
 23 the Secretary stipulate to the entry of a nationwide injunction barring enforcement of  
 24 CMS 1682-R. When the Secretary refused that demand, Plaintiff moved for a  
 25 nationwide preliminary injunction. ECF No. 6. Plaintiff’s briefing was replete with  
 26 claims that the Secretary “denied” his claims “in bad faith.” *See, e.g.*, ECF No. 6 at 1,  
 27 4, 10; ECF No. 22 at 1-2. Plaintiff was not transparent about the fact that the claims  
 28 had been paid, either in his complaint or his preliminary injunction briefing. *See* ECF  
 No. 34 (order directing Plaintiff to provide a full accounting of any claims that had not  
 been paid). It seems reasonable to infer from these early developments that Plaintiff  
 and his counsel hoped to score a quick victory before the true facts became known.

1 CMS 1682-R and to declare that her CGM device was covered by Medicare. *Smith*,  
2 44 F.4th at 1241-42, 1245-46, 1249. The Secretary argued that the claims were moot  
3 due to (1) the adoption of the DME Final Rule; (2) the issuance of TDL 220257; and  
4  
5 (3) the formal rescission of CMS 1682-R through the issuance of CMS 1738-R. *Id.* at  
6 1248. The Court agreed:

7       We dismiss the appeal as moot. The Final Rule concerning future claims  
8 for CGMs, coupled with the recent issuance of Technical Direction Letter  
9 220257 and CMS-1738-R, fully redress Smith’s equitable claims. Vacating  
10 CMS-1682-R and declaring that CGMs are durable medical equipment  
11 covered by Medicare would have no effect because CMS has already  
12 rescinded CMS-1682-R and issued a formal rule classifying CGMs and  
13 their supplies as durable medical equipment. In short, Smith no longer  
suffers from an actual or imminent injury that can be redressed by this  
court.

14 *Id.* at 1246.

15       While not binding on this Court, *Smith* is highly persuasive authority. As the  
16 Tenth Circuit correctly concluded, the DME Final Rule, TDL 220257, and the formal  
17 rescission of CMS 1682-R, taken together, “ensure that pending and future claims for  
18 CGMs . . . will be covered by Medicare.” *Id.* at 1242. Collectively, “these changes  
19 mean that the Secretary no longer has any basis upon which to deny . . . pending or  
20 future claims.” *Id.* at 1248. Any challenge to the legality of CMS 1682-R, and any  
21 request for declaratory or injunctive relief addressed to CMS 1682-R specifically or to  
22 coverage for CGMs in general, is therefore moot. *Id.* at 1242, 1246-47, 1248-50.

26       *Smith* also addresses the “voluntary cessation” exception to mootness, which  
27 the Secretary anticipates Plaintiff will invoke in his response. The voluntary cessation  
28



1 exception provides that a case is not moot when the defendant has stopped engaging in  
2 the challenged conduct, but remains free to resume it again in the future. *Fikre v. Fed.*  
3 *Bureau of Investigation*, 904 F.3d 1033, 1037 (9th Cir. 2018). To obtain a dismissal  
4 on mootness grounds, the defendant must show that “the challenged conduct cannot  
5 reasonably be expected to start up again.” *Id.* The *Smith* Court emphatically rejected  
6 the plaintiff’s reliance on the voluntary cessation exception, holding that there was no  
7 reasonable possibility that the Secretary would continue to deny CGM claims under  
8 CMS 1682-R:  
9

11 [T]here is a minimal risk that the Secretary will suddenly revert to his  
12 rescinded policy of denying CGM claims given the wholesale change in  
13 policy that has developed over the past several years. To undo his  
14 policy recognizing CGMs as durable medical equipment, the Secretary  
15 would need to take the unlikely steps of disavowing his previous  
16 support for the coverage of CGMs, replacing the Final Rule—which  
17 can only be done after a notice and comment period, rescinding the  
18 Technical Direction Letter, and withdrawing CMS-1738-R.

19 \* \* \*

20 It cannot “reasonably be expected” that CMS would suddenly revert to  
21 denying CGM claims when it has gone through the lengthy rulemaking  
22 process and concluded in the Final Rule, Technical Direction Letter,  
23 and CMS-1738-R that CGMs are durable medical equipment covered  
24 by Medicare. Unraveling those regulatory changes seems improbable,  
25 especially given that CMS has determined it to be more cost effective to  
26 pay pending CGM claims rather than continue litigating them.

27 *Id.* at 1251, 1252.

28 The legal claims in *Smith* are virtually identical to the claims Plaintiff is  
pursuing here. From a factual standpoint, the cases are substantially similar. The



1 main distinction between this case and *Smith* is that the Medicare claims at issue here  
2 were paid *before* the challenged administrative decisions were issued, and *before* the  
3 case was filed. That distinction makes the Tenth Circuit’s reasoning even more  
4 persuasive on the facts presented here, especially on the question of voluntary  
5 cessation.  
6

7 The Court should adopt *Smith*’s persuasive reasoning and dismiss the case as  
8 moot in light of the Secretary’s adoption of the DME Final Rule, the issuance of TDL  
9 220257, and the formal rescission of CMS 1682-R, all of which ensure that Plaintiff’s  
10 pending and future CGM claims will be covered by Medicare.  
11

12  
13 **C. Plaintiff’s due process claim fails as a matter of undisputed fact and well-**  
14 **established law.**

15 Plaintiff’s sixth cause of action is a constitutional due process claim under the  
16 Fifth and Fourteenth Amendments. ECF No. 1 at ¶¶ 106-12. The crux of this claim is  
17 that Plaintiff “has a Constitutionally protected property interest in funds due as a result  
18 of qualifying claims submitted to Medicare,” and that Plaintiff was “deprived [of] his  
19 property interest . . . without due process because the Secretary has not appointed a  
20 neutral decision maker to consider [his] claims.” *Id.* at ¶¶ 108-09.  
21  
22

23 This claim fails for a host of reasons. From a factual standpoint, there has been  
24 no deprivation of a “property interest in funds due” because Medicare *paid* the subject  
25 claims. Plaintiff’s allegation that he was “deprived” of that interest by the challenged  
26  
27  
28

1 decisions borders on a Rule 11 violation.<sup>7</sup>

2       Moreover, assuming *arguendo* that a deprivation of a property interest actually  
3 did occur, Plaintiff has not proven that it was *his* property interest that was infringed.  
4 Plaintiff has suggested in prior filings that his supplier, MiniMed, covered the full cost  
5 of the CGM sensors that are the subject of the April 2019 and March 2021 claims.  
6 *See, e.g.*, ECF No. 22 at 10 (“That [Plaintiff] has a CGM at this time is totally  
7 dependent on the *generosity of his supplier* and willingness (to date) to provide a  
8 CGM *without payment*.”) (emphasis added). Documents produced by MiniMed in  
9 response to the Secretary’s subpoena (*see* ECF Nos. 58, 62), appear to confirm that  
10 MiniMed did not charge Plaintiff for any portion of the cost of the sensors. Drake  
11 Decl. ¶¶ 4-6, & Ex. A. The fact that Plaintiff did not pay anything for the sensors  
12 means that he does not have a constitutionally protected right to reimbursement by  
13 Medicare. Any right to reimbursement belongs to MiniMed, not Plaintiff.  
14 Accordingly, there are no facts to support a finding that Plaintiff was deprived of a  
15 “property interest in funds due.”  
16  
17  
18  
19  
20

21       From a legal standpoint, Plaintiff’s due process claim is not cognizable. The  
22 essence of procedural due process is notice and an opportunity to be heard. *Mathews*  
23

---

24 <sup>7</sup> If the Court were to “direct the Secretary to make appropriate payment for the  
25 claims,” as Plaintiff requests in his complaint, *see, e.g.*, ECF No. 1 at ¶ 102, the  
26 Secretary would be paying the claims twice. It is not at all clear how that request  
27 comports with counsel’s duty to ensure Plaintiff’s claims are factually supported,  
28 warranted by existing law, and not presented for an improper purpose. Fed. R. Civ. P.  
11(b).

1 *v. Eldridge*, 424 U.S. 319, 333 (1976). Plaintiff was afforded both. Plaintiff does not  
2 like the decisions reached by the ALJ and the Medicare Appeals Council, but he does  
3 not deny that he was afforded an opportunity to participate in the process.  
4

5 Plaintiff's allegation that the ALJ and Medicare Appeals Council were not  
6 "neutral decision makers" does not save the claim. While a neutral decision maker is  
7 an important component of procedural due process, "neutrality" in this context refers  
8 to the absence of *bias*. See *Clements v. Airport Auth. of Washoe Cnty.*, 69 F.3d 321,  
9 333 (9th Cir. 1995) ("A biased proceeding is not a procedurally adequate one. At a  
10 minimum, Due Process requires a hearing before an impartial tribunal.") (citing *Ward*  
11 *v. Village of Monroeville*, 409 U.S. 57, 59-60 (1972)). Plaintiff has not alleged, much  
12 less proven, that the ALJ and/or the Medicare Appeals Council were biased against  
13 him. To the contrary, the thrust of this claim is that the ALJ and Medicare Appeals  
14 Council were not "neutral" because they *had no choice but to apply CMS 1682-R* to  
15 him and every other CGM claimant. See ECF No. 64 at 9 (colorfully arguing that  
16 ALJs are "partisans beholden to their master" and (in reference to CMS 1682-R) must  
17 follow "whatever ridiculous, illegal, thing [the Secretary] might happen to say").  
18  
19  
20  
21

22 CMS Rulings are precedential. They are "binding on all CMS components,  
23 [and] all HHS components that adjudicate matters under the jurisdiction of CMS,"  
24 including ALJs and the Medicare Appeals Council. 42 C.F.R. § 401.108(c). The fact  
25 that the ALJ and Medicare Appeals Council applied CMS 1682-R in the challenged  
26 decisions is not indicative of bias or partiality. It simply means they were doing their  
27  
28

1 jobs. Plaintiff's frustration that the ALJ and Medicare Appeals Council were not free  
 2 to disregard CMS 1682-R while that ruling was in effect does not amount to a due  
 3 process violation. This claim should be dismissed.

4  
 5 **D. The Court should dismiss the case without prejudice for lack of Article III**  
 6 **jurisdiction, or, alternatively, enter judgment in Plaintiff's favor on Count**  
 7 **II with instructions to vacate the challenged administrative decisions.**

8 For the reasons explained in Section III.A, *supra*, jurisdiction has been lacking  
 9 from the outset because the Secretary paid the subject claims four months before the  
 10 case was filed. As a result, the Court lacks authority to take any action other than to  
 11 dismiss the case without prejudice. Fed. R. Civ. P. 12(h)(3) ("If the court determines  
 12 at any time that it lacks subject-matter jurisdiction, it must dismiss the action."); *Steel*  
 13 *Co. v. Citizens for a Better Env't*, 523 U.S. 83, 94 (1998) ("Without jurisdiction the  
 14 court cannot proceed at all in any cause. Jurisdiction is power to declare the law, and  
 15 when it ceases to exist, the only function remaining to the court is that of announcing  
 16 the fact and dismissing the cause.") (citation omitted); *Barke v. Banks*, 25 F.4th 714,  
 17 721 (9th Cir. 2022) (dismissal for lack of Article III jurisdiction must be without  
 18 prejudice).

19  
 20 As discussed in Section III.B, *supra*, the Secretary's rescission and replacement  
 21 of CMS 1682-R moots Plaintiff's challenge to that administrative ruling and his  
 22 attendant requests for injunctive and declaratory relief. If the Court disagrees with the  
 23 Secretary's mootness analysis and concludes that it has Article III jurisdiction over  
 24 plaintiff's claims, which for the reasons explained it should not,, the appropriate

1 course would be remand the case to the Secretary with instructions to vacate the ALJ  
2 and Medicare Appeals Council decisions that purport to deny coverage pursuant to  
3 CMS 1682-R, as the Secretary asked the Court to do from the very beginning, but  
4 which Plaintiff repeatedly opposed. *See* ECF Nos. 4, 16, 41 (original answer,  
5 amended answer, and second amended answer, all consenting to administrative  
6 remand to vacate the challenged agency decisions). The Court could do so by (1)  
7 entering judgment in Plaintiff's favor on Count II of the Complaint (violation of  
8 5 U.S.C. § 706(2)(A) for agency action "not in accordance with law") because the  
9 ALJ and Medicare Appeals Council decisions from which the plaintiffs appealed to  
10 district court are not in accordance with law in light of the Secretary's new policy;<sup>8</sup>  
11 and (2) entering judgment in the Secretary's favor on all other claims.  
12  
13  
14

#### 15 IV. CONCLUSION

16  
17 The Secretary respectfully requests that the Court dismiss the case without  
18 prejudice for lack of jurisdiction. Alternatively, to the extent jurisdiction has been  
19 established, the Secretary requests that the Court enter judgment in Plaintiff's favor on  
20 Count II of the Complaint, with instructions to vacate the challenged administrative  
21 decisions, and enter judgment in Defendant's favor on all remaining claims.  
22  
23  
24  
25

---

26  
27 <sup>8</sup> That policy applies to any pending or properly appealed claim for reimbursement of  
28 a CGM device or supplies, regardless of date of service, and thus includes Plaintiff's  
two reimbursement claims at issue in this case.

1 DATED this 3rd day of October, 2022.

2 Vanessa R. Waldref  
3 United States Attorney

4 s/John T. Drake  
5 Brian M. Donovan  
6 John T. Drake  
7 Assistant United States Attorneys  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**CERTIFICATE OF SERVICE**

I hereby certify that on October 3, 2022, I caused to be delivered via the method listed below the document to which this Certificate of Service is attached (plus any exhibits and/or attachments) to the following:

<b>NAME &amp; ADDRESS</b>	<b>Method of Delivery</b>
Roger Townsend BRESKIN JOHNSON TOWNSEND 1000 Second Ave., Suite 3670 Seattle, WA 98104	<input checked="" type="checkbox"/> CM/ECF System <input type="checkbox"/> Electronic Mail <input type="checkbox"/> U.S. Mail <input type="checkbox"/> Other: _____
James Pistorino PARRISH LAW OFFICES 788 Washington Road Pittsburgh, PA 15228	<input checked="" type="checkbox"/> CM/ECF System <input type="checkbox"/> Electronic Mail <input type="checkbox"/> U.S. Mail <input type="checkbox"/> Other: _____

*s/John T. Drake*  
John T. Drake